Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy

• Status: Completed
• Trial end date: 2018-09-06
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this multicentre, prospective, double blind, placebo controlled, randomized pilot study is to investigate safety and tolerance of Epigallocatechin-Gallate (EGCG, the major polyphenol in green tea) in patients with muscular dystrophy of the Duchenne type.

In a second step the investigators want to investigate the effect of EGCG on the course of the Duchenne condition.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Treatments: Epigallocatechin gallate

Criteria

Inclusion Criteria:

• Duchenne muscular dystrophy

• age 5-10 years

• ability to walk without support

• informed consent by the parents

Exclusion Criteria:

• another serious organic disease

• further primary psychiatric or neurological diseases

• long-term intake of liver-toxic medicines